Circulation Research, Vol 71, 271-287, Copyright © 1992 by American Heart Association

ARTICLES

Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation

Z Wang, P Page and S Nattel
Department of Medicine, Montreal Heart Institute, Quebec, Canada.

Class Ic antiarrhythmic drugs are effective in the treatment of atrial fibrillation, but their mechanism of action is unknown. In previous work, we have found that flecainide causes tachycardia-dependent increases in atrial action potential duration (APD) and effective refractory period (ERP) by reducing APD accommodation to heart rate. The present study was designed to evaluate the efficacy and mechanisms of action of flecainide in an experimental model of sustained atrial fibrillation (AF). AF was produced by a brief burst of atrial pacing in the presence of vagal stimulation and persisted spontaneously until vagal stimulation was stopped. The actions of flecainide at two dose levels were compared with those of isotonic glucose placebo in each dog, with a randomized order of blinded drug administration. Flecainide terminated AF in all 16 dogs, while glucose was effective in none (p less than 0.0001). Flecainide increased atrial ERP and reduced conduction velocity in a tachycardia-dependent manner. Doses of flecainide that converted AF resulted in larger changes in ERP than in conduction velocity, increasing the minimum path-length capable of supporting reentry (wavelength). In addition, flecainide reduced regional heterogeneity in ERP and wavelength, an action opposite that of vagal stimulation. Atrial epicardial mapping with a 112-electrode atrial array was used to study the mechanism of flecainide action on AF. Under control conditions, multiple small zones of reentry coexisted. Flecainide progressively increased the size of reentry circuits, decreased their number, and slowed the frequency of atrial activation until the arrhythmia finally terminated; all changes were compatible with an increase in wavelength. We conclude that flecainide terminates atrial fibrillation in this experimental model by causing tachycardia-dependent increases in atrial ERP, which increase the wavelength at the rapid rates characteristic of AF to the point that the arrhythmia can no longer sustain itself.

This article has been cited by other articles:

				K. Nishida, G. Michael, D. Dobrev, and S. Nattel Animal models for atrial fibrillation: clinical insights and scientific opportunities Europace, October 29, 2009; (2009) eup328v1. [Abstract] [Full Text] [PDF]

				C. Zhao, J. Qi, X. Liu, H. Chen, J. Li, Y. Liu, L. Liang, Y. Zhang, J. Xiao, L. Li, et al. Refractoriness of the Sheep Superior Vena Cava Myocardial Sleeve Experimental Biology and Medicine, November 1, 2008; 233(11): 1441 - 1447. [Abstract] [Full Text] [PDF]

				P. Comtois, M. Sakabe, E. J. Vigmond, M. Munoz, A. Texier, A. Shiroshita-Takeshita, and S. Nattel Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1489 - H1504. [Abstract] [Full Text] [PDF]

				J.-F. Sarrazin, G. Comeau, P. Daleau, J. Kingma, I. Plante, D. Fournier, and F. Molin Reduced Incidence of Vagally Induced Atrial Fibrillation and Expression Levels of Connexins by n-3 Polyunsaturated Fatty Acids in Dogs J. Am. Coll. Cardiol., October 9, 2007; 50(15): 1505 - 1512. [Abstract] [Full Text] [PDF]

				N. Lellouche, E. Buch, A. Celigoj, C. Siegerman, D. Cesario, C. De Diego, A. Mahajan, N. G. Boyle, I. Wiener, A. Garfinkel, et al. Functional Characterization of Atrial Electrograms in Sinus Rhythm Delineates Sites of Parasympathetic Innervation in Patients With Paroxysmal Atrial Fibrillation J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1324 - 1331. [Abstract] [Full Text] [PDF]

				L. Rivard, H. Sinno, A. Shiroshita-Takeshita, G. Schram, T.-K. Leung, and S. Nattel The pharmacological response of ischemia-related atrial fibrillation in dogs: Evidence for substrate-specific efficacy Cardiovasc Res, April 1, 2007; 74(1): 104 - 113. [Abstract] [Full Text] [PDF]

				M. Haissaguerre, M. Hocini, P. Sanders, Y. Takahashi, M. Rotter, F. Sacher, T. Rostock, L.-F. Hsu, A. Jonsson, M. D. O'Neill, et al. Localized Sources Maintaining Atrial Fibrillation Organized by Prior Ablation Circulation, February 7, 2006; 113(5): 616 - 625. [Abstract] [Full Text] [PDF]

				R. Zou, J. Kneller, L. J. Leon, and S. Nattel Substrate size as a determinant of fibrillatory activity maintenance in a mathematical model of canine atrium Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1002 - H1012. [Abstract] [Full Text] [PDF]

				D. Herrera, A. Mamarbachi, M. Simoes, L. Parent, R. Sauve, Z. Wang, and S. Nattel A Single Residue in the S6 Transmembrane Domain Governs the Differential Flecainide Sensitivity of Voltage-Gated Potassium Channels Mol. Pharmacol., August 1, 2005; 68(2): 305 - 316. [Abstract] [Full Text] [PDF]

				J. Kneller*, J. Kalifa*, R. Zou, A. V. Zaitsev, M. Warren, O. Berenfeld, E. J. Vigmond, L. J. Leon, S. Nattel, and J. Jalife Mechanisms of Atrial Fibrillation Termination by Pure Sodium Channel Blockade in an Ionically-Realistic Mathematical Model Circ. Res., March 18, 2005; 96(5): e35 - e47. [Abstract] [Full Text] [PDF]

				J. Reisinger, E. Gatterer, W. Lang, T. Vanicek, G. Eisserer, T. Bachleitner, C. Niemeth, F. Aicher, W. Grander, G. Heinze, et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset Eur. Heart J., August 1, 2004; 25(15): 1318 - 1324. [Abstract] [Full Text] [PDF]

				M. Haissaguerre, P. Sanders, M. Hocini, L.-F. Hsu, D. C. Shah, C. Scavee, Y. Takahashi, M. Rotter, J.-L. Pasquie, S. Garrigue, et al. Changes in Atrial Fibrillation Cycle Length and Inducibility During Catheter Ablation and Their Relation to Outcome Circulation, June 22, 2004; 109(24): 3007 - 3013. [Abstract] [Full Text] [PDF]

				A. G. KLEBER and Y. RUDY Basic Mechanisms of Cardiac Impulse Propagation and Associated Arrhythmias Physiol Rev, April 1, 2004; 84(2): 431 - 488. [Abstract] [Full Text] [PDF]

				N. Decher, B. Pirard, F. Bundis, S. Peukert, K.-H. Baringhaus, A. E. Busch, K. Steinmeyer, and M. C. Sanguinetti Molecular Basis for Kv1.5 Channel Block: CONSERVATION OF DRUG BINDING SITES AMONG VOLTAGE-GATED K+ CHANNELS J. Biol. Chem., January 2, 2004; 279(1): 394 - 400. [Abstract] [Full Text] [PDF]

				G.L. Botto, M. Luzi, and A. Sagone Atrial fibrillation: the remodelling phenomenon Eur. Heart J. Suppl., September 1, 2003; 5(suppl_H): H1 - H7. [Abstract] [PDF]

				M. Bettoni and M. Zimmermann Autonomic Tone Variations Before the Onset of Paroxysmal Atrial Fibrillation Circulation, June 11, 2002; 105(23): 2753 - 2759. [Abstract] [Full Text] [PDF]

				J. Jalife, O. Berenfeld, and M. Mansour Mother rotors and fibrillatory conduction: a mechanism of atrial fibrillation Cardiovasc Res, May 1, 2002; 54(2): 204 - 216. [Abstract] [Full Text] [PDF]

				S. Nattel Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res, May 1, 2002; 54(2): 347 - 360. [Abstract] [Full Text] [PDF]

				D. Dobrev, E. Graf, E. Wettwer, H. M. Himmel, O. Hala, C. Doerfel, T. Christ, S. Schuler, and U. Ravens Molecular Basis of Downregulation of G-Protein-Coupled Inward Rectifying K+ Current (IK,ACh) in Chronic Human Atrial Fibrillation: Decrease in GIRK4 mRNA Correlates With Reduced IK,ACh and Muscarinic Receptor-Mediated Shortening of Action Potentials Circulation, November 20, 2001; 104(21): 2551 - 2557. [Abstract] [Full Text] [PDF]

				B. Zrenner, G. Ndrepepa, M. R. Karch, M. A. E. Schneider, J.u. Schreieck, A. Schomig, and C. Schmitt Electrophysiologic characteristics of paroxysmal and chronic atrial fibrillation in human right atrium J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1143 - 1149. [Abstract] [Full Text] [PDF]

				M. M. Rahme, G. Ungab, M. Wadhwa, F. Al-Kandari, B. Yao, A. Gupta, K. Lee, H.-Y. Kim, and G. K. Feld Electrophysiologic and Antiarrhythmic Effects of the New Class III Antiarrhythmic Drug KCB-328 in Experimental Canine Atrial Flutter Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2001; 6(3): 297 - 306. [Abstract] [PDF]

				C. W. Israel, J. R. Ehrlich, G. Gronefeld, A. Klesius, T. Lawo, B. Lemke, and S. H. Hohnloser Prevalence, characteristics and clinical implications of regular atrial tachyarrhythmias in patients with atrial fibrillation: insights from a study using a new implantable device J. Am. Coll. Cardiol., August 1, 2001; 38(2): 355 - 363. [Abstract] [Full Text] [PDF]

				P. Schauerte, B. J. Scherlag, J. Pitha, M. A. Scherlag, D. Reynolds, R. Lazzara, and W. M. Jackman Catheter Ablation of Cardiac Autonomic Nerves for Prevention of Vagal Atrial Fibrillation Circulation, November 28, 2000; 102(22): 2774 - 2780. [Abstract] [Full Text] [PDF]

				H. J. Sih, D. P. Zipes, E. J. Berbari, D. E. Adams, and J. E. Olgin Differences in organization between acute and chronic atrial fibrillation in dogs J. Am. Coll. Cardiol., September 1, 2000; 36(3): 924 - 931. [Abstract] [Full Text] [PDF]

				M. C. E. F. Wijffels, R. Dorland, F. Mast, and M. A. Allessie Widening of the Excitable Gap During Pharmacological Cardioversion of Atrial Fibrillation in the Goat : Effects of Cibenzoline, Hydroquinidine, Flecainide, and d-Sotalol Circulation, July 11, 2000; 102(2): 260 - 267. [Abstract] [Full Text] [PDF]

				M. M. Scheinman Mechanisms of atrial fibrillation: is a cure at hand? J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1687 - 1692. [Abstract] [Full Text] [PDF]

				F. J. Chorro, J. Canoves, J. Guerrero, L. Mainar, J. Sanchis, L. Such, and V. Lopez-Merino Alteration of Ventricular Fibrillation by Flecainide, Verapamil, and Sotalol : An Experimental Study Circulation, April 4, 2000; 101(13): 1606 - 1615. [Abstract] [Full Text] [PDF]

				R.J Schilling, A.H Kadish, N.S Peters, J Goldberger, and D.W. Davies Endocardial mapping of atrial fibrillation in the human right atrium using a non-contact catheter Eur. Heart J., April 1, 2000; 21(7): 550 - 564. [Abstract] [PDF]

				L. Yue, J. L. Feng, Z. Wang, and S. Nattel Effects of ambasilide, quinidine, flecainide and verapamil on ultra-rapid delayed rectifier potassium currents in canine atrial myocytes Cardiovasc Res, April 1, 2000; 46(1): 151 - 161. [Abstract] [Full Text] [PDF]

				K. Shinagawa, H. Mitamura, A. Takeshita, T. Sato, H. Kanki, S. Takatsuki, and S. Ogawa Determination of refractory periods and conduction velocity during atrial fibrillation using atrial capture in dogs: Direct assessment of the wavelength and its modulation by a sodium channel blocker, pilsicainide J. Am. Coll. Cardiol., January 1, 2000; 35(1): 246 - 253. [Abstract] [Full Text] [PDF]

				D. Li, S. Fareh, T. K. Leung, and S. Nattel Promotion of Atrial Fibrillation by Heart Failure in Dogs : Atrial Remodeling of a Different Sort Circulation, July 6, 1999; 100(1): 87 - 95. [Abstract] [Full Text] [PDF]

				S. Nattel Atrial electrophysiological remodeling caused by rapid atrial activation: underlying mechanisms and clinical relevance to atrial fibrillation Cardiovasc Res, May 1, 1999; 42(2): 298 - 308. [Abstract] [Full Text] [PDF]

				W.-C. Yu, S.-H. Lee, C.-T. Tai, C.-F. Tsai, M.-H. Hsieh, C.-C. Chen, Y.-A. Ding, M.-S. Chang, and S.-A. Chen Reversal of atrial electrical remodeling following cardioversion of long-standing atrial fibrillation in man Cardiovasc Res, May 1, 1999; 42(2): 470 - 476. [Abstract] [Full Text] [PDF]

				T. Uchida, M. Yashima, M. Gotoh, Z. Qu, A. Garfinkel, J. N. Weiss, M. C. Fishbein, W. J. Mandel, P.-S. Chen, and H. S. Karagueuzian Mechanism of Acceleration of Functional Reentry in the Ventricle : Effects of ATP-Sensitive Potassium Channel Opener Circulation, February 9, 1999; 99(5): 704 - 712. [Abstract] [Full Text] [PDF]

				G. Boriani, M. Biffi, A. Capucci, G. Bronzetti, G. M. Ayers, R. Zannoli, A. Branzi, and B. Magnani Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation J. Am. Coll. Cardiol., February 1, 1999; 33(2): 333 - 341. [Abstract] [Full Text] [PDF]

				S. Fareh, C. Villemaire, and S. Nattel Importance of Refractoriness Heterogeneity in the Enhanced Vulnerability to Atrial Fibrillation Induction Caused by Tachycardia-Induced Atrial Electrical Remodeling Circulation, November 17, 1998; 98(20): 2202 - 2209. [Abstract] [Full Text] [PDF]

				W.-C. Yu, S.-A. Chen, S.-H. Lee, C.-T. Tai, A.-N. Feng, B. I.-T. Kuo, Y.-A. Ding, and M.-S. Chang Tachycardia-Induced Change of Atrial Refractory Period in Humans : Rate Dependency and Effects of Antiarrhythmic Drugs Circulation, June 16, 1998; 97(23): 2331 - 2337. [Abstract] [Full Text] [PDF]

				F. Gaita, R. Riccardi, L. Calo, M. Scaglione, L. Garberoglio, R. Antolini, M. Kirchner, F. Lamberti, and E. Richiardi Atrial Mapping and Radiofrequency Catheter Ablation in Patients With Idiopathic Atrial Fibrillation : Electrophysiological Findings and Ablation Results Circulation, June 2, 1998; 97(21): 2136 - 2145. [Abstract] [Full Text] [PDF]

				M. R. Ujhelyi, J. J. Sims, and A. W. Miller High-dose lidocaine does not affect defibrillation efficacy: implications for defibrillation mechanisms Am J Physiol Heart Circ Physiol, April 1, 1998; 274(4): H1113 - H1120. [Abstract] [Full Text] [PDF]

				S. Nattel, L. Liu, and D. St-Georges Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties Cardiovasc Res, March 1, 1998; 37(3): 627 - 635. [Abstract] [Full Text] [PDF]

				R. Gaspo, R. F. Bosch, E. Bou-Abboud, and S. Nattel Tachycardia-Induced Changes in Na+ Current in a Chronic Dog Model of Atrial Fibrillation Circ. Res., December 19, 1997; 81(6): 1045 - 1052. [Abstract] [Full Text]

				B. S. Stambler, M. A. Wood, and K. A. Ellenbogen Antiarrhythmic Actions of Intravenous Ibutilide Compared With Procainamide During Human Atrial Flutter and Fibrillation : Electrophysiological Determinants of Enhanced Conversion Efficacy Circulation, December 16, 1997; 96(12): 4298 - 4306. [Abstract] [Full Text]

				R. Gaspo, R. F. Bosch, M. Talajic, and S. Nattel Functional Mechanisms Underlying Tachycardia-Induced Sustained Atrial Fibrillation in a Chronic Dog Model Circulation, December 2, 1997; 96(11): 4027 - 4035. [Abstract] [Full Text]

				R. G. Tieleman, C. D. J. De Langen, I. C. Van Gelder, P. J. de Kam, J. Grandjean, K. J. Bel, M. C. E. F. Wijffels, M. A. Allessie, and H. J. G. M. Crijns Verapamil Reduces Tachycardia-Induced Electrical Remodeling of the Atria Circulation, April 1, 1997; 95(7): 1945 - 1953. [Abstract] [Full Text]

				K. Kumagai, C. Khrestian, and A. L. Waldo Simultaneous Multisite Mapping Studies During Induced Atrial Fibrillation in the Sterile Pericarditis Model: Insights Into the Mechanism of its Maintenance Circulation, January 21, 1997; 95(2): 511 - 521. [Abstract] [Full Text]

				G. K. Feld and Yongmei Cha Electrophysiologic Effects of the New Class III Antiarrhythmic Drug Dofetilide in an Experimental Canine Model of Pacing-induced Atrial Fibrillation Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(3): 195 - 203. [Abstract] [PDF]

				B. S. Stambler, M. A. Wood, K. A. Ellenbogen, K. T. Perry, L. K. Wakefield, and J. T. VanderLugt Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or Fibrillation Circulation, October 1, 1996; 94(7): 1613 - 1621. [Abstract] [Full Text]

				M. C.E.F. Wijffels, C. J.H.J. Kirchhof, R. Dorland, and M. A. Allessie Atrial Fibrillation Begets Atrial Fibrillation : A Study in Awake Chronically Instrumented Goats Circulation, October 1, 1995; 92(7): 1954 - 1968. [Abstract] [Full Text]

				J. Coromilas, A. E. Saltman, B. Waldecker, S. M. Dillon, and A. L. Wit Electrophysiological Effects of Flecainide on Anisotropic Conduction and Reentry in Infarcted Canine Hearts Circulation, April 15, 1995; 91(8): 2245 - 2263. [Abstract] [Full Text]